BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15892962)

  • 1. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
    Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
    Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
    Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
    Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated immune responses to COPV early proteins.
    Jain S; Moore RA; Anderson DM; Gough GW; Stanley MA
    Virology; 2006 Dec 5-20; 356(1-2):23-34. PubMed ID: 16949120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
    Ghim S; Newsome J; Bell J; Sundberg JP; Schlegel R; Jenson AB
    Exp Mol Pathol; 2000 Jun; 68(3):147-51. PubMed ID: 10816383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
    Smahel M; Síma P; Ludvíková V; Vonka V
    Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
    Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
    J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
    Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
    Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
    Stanley MA; Moore RA; Nicholls PK; Santos EB; Thomsen L; Parry N; Walcott S; Gough G
    Vaccine; 2001 Apr; 19(20-22):2783-92. PubMed ID: 11282188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
    Nicholls PK; Klaunberg BA; Moore RA; Santos EB; Parry NR; Gough GW; Stanley MA
    Virology; 1999 Dec; 265(2):365-74. PubMed ID: 10600607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
    Suzich JA; Ghim SJ; Palmer-Hill FJ; White WI; Tamura JK; Bell JA; Newsome JA; Jenson AB; Schlegel R
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11553-7. PubMed ID: 8524802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW; Anderson ME; Wu S; Lee JH
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
    Herd KA; Harvey T; Khromykh AA; Tindle RW
    Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
    Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
    Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.